AegirBio AB Logo

AegirBio AB

Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.

AEGIR | ST

Overview

Corporate Details

ISIN(s):
SE0014401121 (+3 more)
LEI:
549300MWGS283WZLYI10
Country:
Sweden
Address:
Scheelevägen 27, 223 63 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Magnasense AB, formerly AegirBio AB, is a diagnostics company specializing in developing innovative, saliva-based solutions for health monitoring. The company's core technology platform enables the creation of user-friendly, non-invasive tests for personalized diagnostics. Magnasense focuses on preventative care, such as oral health, and chronic disease management, particularly through Therapeutic Drug Monitoring (TDM) to optimize the dosage of biological drugs. Its products are designed for both professional healthcare settings and at-home use, aiming to make precision diagnostic testing more accessible, simple, and convenient for individuals and providers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AegirBio AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AegirBio AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AegirBio AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-04-04 Bradley Messmer Other Other 499,829 N/A
2023-01-16 Fredrik Häglund Other Other 45,244 85,511.16 SEK
2022-12-09 Raphaela Heussen Other Other 37,689 N/A
2021-10-27 Martin Linde Other Other 370,000 N/A
2021-10-26 Anders Ingvarsson Other Other 120,000 N/A
2021-09-22 Patrik Elfwing Other Buy 2,000 519,200.00 SEK
2021-09-16 Anders Ingvarsson Other Other 120,000 N/A
2021-06-28 Gunnar Telhammar Other Sell 460 47,288.00 SEK
2021-06-17 Fredrik Häglund Other Other 245,397 1,840,477.50 SEK
2021-06-17 Martin Linde Other Other 160,263 1,169,919.90 SEK

Peer Companies

IN8BIO, INC. Logo
Clinical-stage biopharma developing gamma-delta T cell therapies for solid & hematological tumors.
United States of America
INAB
Develops targeted dermatology & oncology therapies using unique formulation & delivery technologies.
United Kingdom
INC
INCYTE CORP Logo
Develops proprietary therapeutics for serious unmet needs in oncology and inflammation.
United States of America
INCY
Indaptus Therapeutics, Inc. Logo
Develops immunotherapies using engineered bacteria to treat cancer and viral infections.
United States of America
INDP
Indivior PLC Logo
Develops pharmaceuticals for opioid use disorder, addiction, and serious mental illnesses.
United Kingdom
INDV
Infant Bacterial Therapeutics Logo
Develops live bacterial medicines to prevent rare, severe gut diseases in premature infants.
Sweden
IBT
InflaRx N.V. Logo
Develops complement system inhibitors for severe inflammatory diseases and immuno-dermatology.
United States of America
IFRX
Inhibikase Therapeutics, Inc. Logo
Develops kinase inhibitors to treat neurodegenerative diseases like Parkinson's.
United States of America
IKT
Inhibrx Biosciences, Inc. Logo
Clinical-stage biopharma developing novel biologic therapies for life-threatening cancers.
United States of America
INBX
InMed Pharmaceuticals Inc. Logo
Develops cannabinoid drugs for unmet medical needs and supplies rare cannabinoids for B2B wellness.
United States of America
INM

Talk to a Data Expert

Have a question? We'll get back to you promptly.